May 5, 2023 7:37am
Uncle Algorithms has saved the week so far, so is the cell and gene therapy sector in which hand – the weak or the strong?
Earnings: Editas Medicine (EDIT)
Pre-open indications: 4 Positive and 1 Negative indications
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday
Dow futures are UP +0.47% or (+155 points), S&P futures are UP +0.61% or (+24 point) and NASDAQ futures are UP +0.62% or (+82 points) early in the pre-open – so far
Stock futures rose Friday after Apple posted its earnings, while investors waited for the release of fresh U.S. jobs data,
European shuffled higher,
Asia-Pacific markets were mixed.
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Thursday, “indexes popped after the Fed pushing through its 10th rate hike after the Dow closed UP +55 points (+0.16%), the S&P closed UP +9.75 points (+0.24%) while the Nasdaq closed UP +34 points (+0.26%),”
Indexes are headed for a week of losses — the worst performance for all three since March 10. The S&P 500 is off 2.6%, while the Nasdaq is off 2.1%. The Dow is down 2.8%.
Economic Data Docket: jobs report - the latest unemployment rate and information on wage growth
· Economists predict that 180,000 jobs were added
Thursday’s (5/4) … RegMed Investors’ (RMi) closing bell: “barely wavers by earnings outcomes. What a difference a session makes.” … https://www.regmedinvestors.com/articles/12945
RegMed Investors (RMi) Research Note: Upcoming Q1/23 earnings reporting dates … https://www.regmedinvestors.com/articles/12923
Ebb and flow:
Q2/23 – May – 1 negative and 3 positive closes
· April ended - 1 holiday, 8 positive close and 11 negative closes
Q1/23 –
· March – ended with 10 positive and 13 negative closes
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive Indications:
Thursday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Agenus (AGEN) closed up +$0.04 with a positive +$0.03 or +1.96% pre-open indication.
BioLife Solution (BLFS) closed up +$0.20 with a positive +$0.36 or +2.01% aftermarket indication.
Ionis Pharmaceuticals (IONS) closed up +$1.25 with a positive +$0.52 or +1.45% pre-open indication
Verve Therapeutics (VERV) closed up +$0.16 with a positive +$0.33 or +2.02% aftermarket indication
Negative Indications:
Thursday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Vericel (VCEL) closed up +$0.54 with a negative -0.17 or -0.52% aftermarket indication.
The BOTTOM LINE: I try to keep it simple and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
It has been said that, “Sentiment surveys are contrarian indicators. The more optimism found, the greater the risk in stocks. The greater the pessimism, the less risk.” <Scott Schnipper, CNBC>
This week’s special, sector earnings are rolling out …
Could the cell and gene therapy sector could experience the “flight of Icarus” … since “our” universe have oscillated between gains and losses since the first of 2023!
There are really three camps, electronic algorithms, traders versus investors who STILL don’t comprehend if the worst is behind us and those “entities” that continue to focus on tailwinds and not headwinds?
Reiterating, “More frequently right than consequentially wrong … “The rubber is hitting the road, so those companies have to do quite well to justify it.” What is the “it” – as LPS (loss-per-share) numbers facilitate downslides.”
Investors should STILL be hesitant to add to positions re concerns of electronic trading i.e., algorithms seem to be the only ones leading any upside – go with flow.
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!
At ANY time, this week, be ready to take partial profits and exit losers.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
